All News

syringe,needle,vaccine

3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients

Jack Cush, MD

ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third

Read Article
COVID Test Antibody

Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

MedPage Today

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Read Article
2021,year

2021 Rheumatology Year in Review

Jack Cush, MD

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
covid coronavirus virus

New Onset Rheumatic Disorders with COVID-19 Infection

Jack Cush, MD

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.

Read Article
GCA temporal artery

Giant Cell Arteritis Novel Treatment Options

Richard Conway, MBBChBAO, PhD

Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.

Read Article
Giant-Cell_Vasculitis.jpg

Top vasculitis takeaways from ACR 2021

Janet Pope, MD, MPH, FRCPC

There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis. 

Read Article
audience learn

Day 4 Report from ACR21

Jack Cush, MD

My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.

Read Article
Best of 2021: Cutaneous manifestations of ANCA-assoc vasculitis studied in 1184 GPA, MPA, EGPA pts and found to assoc w/ more severe disease. Common were petechiae/purpura (15%); allergic Sxs such as pruritus, urticaria, were more common in EGPA

Dr. John Cush RheumNow ( View Tweet)

Best of 2021: Avacopan - Is it Really a Win for ANCA-Associated Vasculitis? The NEJM has reported the results of a study showing that avacopan, a C5a receptor inhibitor, is as effective as steroids at treating patients with ANCA-AAV. https://t.co/cm9PX66zE7 https://t.co/e7S5C6eugK

Links:

Dr. John Cush RheumNow ( View Tweet)
NEJM Clinical Images - Tongue Necrosis in Giant Cell Arteritis. 74-yoF w/ 3-day hx of HA and tongue swelling/pain, & blindness in the right eye. Tongue was ulcerated, R temporal artery thickened. ESR 42 CRP 169 mg/L. Read rest of story... https://t.co/DDgu0UpZN9 https://t.co/BPlIEmRjg3

Links:

Dr. John Cush RheumNow ( View Tweet)
Genes and Obesity Tied to Higher Gout Risk in Women Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found. https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Giant Cell Arteritis Novel Treatment Options https://t.co/ywqGZNmHOa https://t.co/2hLESL1RjO

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: COVID-19 in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica Dr. Bella Mehta ( @bella_mehta) interviews Dr. Sebastian Sattui about abstract #0952 presented at the #ACR21 annual meeting. https://t.co/UN66qOGqRd

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Session Review: Dr. Arthur Kavanaugh discussed the FDA session presented at the ACR21meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more. https://t.co/5YkbzDv0YR https://t.co/MS9KNIfm2m

Links:

Dr. John Cush RheumNow ( View Tweet)
COVID-19 in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica Dr. Bella Mehta ( @bella_mehta) interviews Dr. Sebastian Sattui about abstract #0952 presented at the #ACR21 annual meeting. https://t.co/BYyz0Xj1Fj

Links:

Dr. John Cush RheumNow ( View Tweet)

In case you missed it… Watch: What's Cool and Hot in Vasculitis with Dr. Janet Pope (@Janetbirdope ) #ACR21 https://t.co/JbhQWeejy7 https://t.co/qlCCk3MXKu

Links:

Dr. John Cush RheumNow ( View Tweet)
📢No difference in ESRD or mortality with RTX-based vs CYC-based induction regimen in ANCA #Vasculitis #ACR21 https://t.co/Bdz5t2uyHi
Guy Katz, MD GuyKatzMD ( View Tweet)
#ACR21 #ACR2021 Clinical Pearls 🚨 Thread Alert 1/n 💥AAV does not typically cause hard palate lesions➡️consider: Cocaine induced midline destructive lesion(HNE+)/Malignancy 💥Limited GPA can be ANCA negetive in 50% 💥 oral cavity examination is a must in Rheum https://t.co/RxkLiGdcJt
EnvisionRheumat ERheumat ( View Tweet)
#ACR21 TM24. Hydralazine-induced ANCA vasculitis presenting with chondritis. Labs: +ANA +Anti-histone +p-ANCA, +MPO and +PR3 @Rheumnow https://t.co/YQvqj0vCHp https://t.co/LPyVYYzLtI

Links:

Eric Dein ericdeinmd ( View Tweet)
#ACR21 2022 ACR/EULAR GPA Criteria ▶️Classification, NOT diagnostic! ⭐️Clinical, lab, imaging, and biopsy criteria ⭐️+5 pts for cANCA or PR3, negative pts for pANCA or MPO, or eosinophilia @RheumNow https://t.co/6YWmabNzuH https://t.co/vg8zaFt5dR

Links:

Eric Dein ericdeinmd ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×